PhRMA Announces Support for 7-Day Script Limits to Help Combat the Opioid Epidemic

September 29, 2017 | Addiction Policy Forum
two hands putting together puzzle pieces
This Wednesday, September 27th, PhRMA (The Pharmaceutical Research and Manufacturers of America) announced their support for seven-day script limits on opioid medications to treat acute pain. PhRMA has been working closely with the President’s Commission on Combating Drug Addiction and the Opioid Crisis, NIH, and the FDA, and hopes that script limits for acute pain will help curb the over-prescription of opioid medication and prevent excess medication from falling into the wrong hands.
“Appropriate script limits, when combined with improved prescriber education and better coverage of treatment alternatives, can help ensure proper prescribing and reduce the risk of abuse. Given the scope and scale of this crisis, we believe this is the right thing to do.”- Stephen J. Ubl, PhRMA President and CEO
While PhRMA recognizes the important role that opioid medications can have in pain management protocol, their stance reflects a growing trend amongst professionals, advocates, and legislators, who agree that, with notable exceptions, a seven-day prescription for opioid medication is sufficient for the needs of most patients.

Read the PhRMA press release